Respiratorius AB (publ) (XSAT:RESP)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.320
+0.015 (1.15%)
At close: Mar 17, 2026
Market Cap10.43M -67.0%
Revenue (ttm)n/a
Net Income-6.95M
EPS-1.17
Shares Out7.90M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume11,222
Average Volume16,105
Open1.315
Previous Close1.305
Day's Range1.315 - 1.380
52-Week Range1.190 - 10.500
Beta1.69
RSI44.32
Earnings DateMay 19, 2026

About Respiratorius AB

Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company’s products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 1
Stock Exchange Spotlight Stock Market
Ticker Symbol RESP
Full Company Profile

Financial Performance

Financial Statements